In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ligand buys Neurogen for stock plus contingent value rights

Executive Summary

Drug discovery player Ligand Pharmaceuticals is issuing stock to acquire publicly held Neurogen (small-molecule CNS drug candidates), which is also entitled to contingent value rights (CVRs). Based on ten-day stock average prior to deal announcement, the transaction is valued at $11.7mm, plus at least $7mm in potential earn-outs.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies